JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2017, Vol. 55 ›› Issue (11): 80-84.doi: 10.6040/j.issn.1671-7554.0.2016.1630

Previous Articles     Next Articles

Price and the accessibility of essential medicines for the elderly with chronic diseases in the Asia Pacific Region

JIANG Mengya1, LOU Hongxiang1, SUN Qiang2, WANG Haipeng2   

  1. 1. School of Pharmacy, Shandong University, Jinan 250012, Shandong, China;
    2. School of Health Care Management, Key Laboratory for Health Economic and Policy of National Health and Family Planning Commission, Shandong University, Jinan 250012, Shandong, China
  • Received:2016-12-07 Online:2017-11-10 Published:2017-11-10

PDF (PC)

205

Abstract: Objective To study the price and accessibility of essential medicines for the elderly with chronic diseases in the six countries of Asia Pacific, and to provide evidence and policy recommendations. Methods The secondary data, which were adjusted according to the inflation/deflation, were acquired from the researches of WHO/HAI and analyzed. Results The availability values of lowest price generic and originator brand in public hospital in the six countries were 5.0%-80.0% and 1.8%-15.4%, while those in private hospital were 11.7%-54.5% and 10.0%-65.6%. The affordability values of lowest price generic and originator brand in public hosipital were 0-1.2 and 0-5.0 times of daily wages, while those in private hospital were 0.3-2.0 and 1.2-7.0 times of daily wages. The median price ratios(MPRs)of lowest price generic and originator brand in public hospital were 0-32.88 and 0-79.13, while those in private hospital were 0.92-46.21 and 13.84-103.75. Conclusion The availability of essential medicines for chronic diseases in the six countries is low, the price of the medicines is higher than the international reference price, and the affordability of the medicine is poor. The accessibility of the medicine must be improved.

Key words: Essential medicines for chronic diseases, Accessibility, Asia Pacific Region, Price

CLC Number: 

  • R956
[1] World Health Organization. Regional framework for action on ageing and health in the Western Pacific(2014-2019)[EB/OL].(2014)[2016-12-07]. http://iris.wpro.who.int/bitstream/handle/10665.1/10422/9789290616566_eng.pdf.
[2] 陆慧敏.人口老龄化与老年人口健康及疾病问题的研究进展[J].世界最新医学信息文摘, 2016, 16(4): 39-40.
[3] WHO, HAI. Medicine prices: a new approach to measurement. Working draft for field testing and revision[EB/OL].(2010-03-01)[2016-12-07]. http://www.haiweb.org/medicineprices/manual/manuals/MedicinePrices.pdf.
[4] 管晓东,史录文.基于WHO/HAI标准调查法的我国基本药物可及性评价方法研究[J].中国药房, 2013, 24(24): 2212-2215. GUAN Xiaodong, SHI Luwen. Study on evaluation method for the accessibility of essential medicine in China based on WHO/HAI standardized approach[J]. China Pharmacy, 2013, 24(24): 2212-2215.
[5] 李萍,王迪飞,吕景睿,等.标准化药品价格调查法及其在我国应用的思考[J].医学与社会, 2010, 23(3): 33-35. LI Ping, WANG Difei, LÜ Jingrui, et al. The methodology of investigation of standardization of drug price and use for reference[J]. Medicine and Society, 2010, 23(3): 33-35.
[6] Frye JE. International drug price indicator guide[EB/OL].(2012)[2016-12-07]. http://www.msh.org/sites/msh.org/files/international-drug-price-indicator-guide.pdf.
[7] Gelders S, Ewen M, Noguchi N, et al. Price, availability and affordability: an international comparison of chronic disease medicines[EB/OL].(2006)[2016-12-07]. http://apps.who.int/iris/bitstream/10665/116493/1/dsa560.pdf.
[8] 罗莎,马爱霞.WHO/HAI药品价格评价及应用介绍[J].中国药物经济学, 2010(5): 73-80.
[9] Comparing price data from different surveys[EB/OL].(2007)[2016-12-07]. http://www.haiweb.org/medicineprices/manual/comparing.html.
[10] Batangan DB, Echavez C, Santiago A, et al. The prices people have to pay for medicines in the Philippines[EB/OL].(2005)[2016-12-07]. http://www. haiweb. org/medicineprices/surveys/200502PH/sdocs/survey_report. pdf.
[11] Nguyen AT, Knight R, Mant A, et al. Medicine prices, availability, and affordability in Vietnam[J]. Southern Med Review, 2009, 2(2): 2-9.
[12] Babar ZUD, Ibrahim MIN, Singh H, et al. A survey of medicine prices, availability, affordability and price components in Malaysia using the who/hai Methodology[EB/OL].(2005-10)[2016-12-07]. https://www.researchgate.net/publication/274962435_A_SURVEY_OF_MEDICINE_PRICES_AVAILABILITY_AFFORDABILITY_AND_PRICE_COMPONENTS_IN_MALAYSIA_USING_THE_WHOHAI_METHODOLOGY.
[13] Fang Y. Medicine prices, availability and affordability in Shaanxi Province, western China[EB/OL].(2012-09)[2016-12-07]. http://www.haiweb.org/medicineprices/13082013/2010_survey_report_shaanxi.pdf.
[14] 武丽娜,魏德宏,陈琛,等.陕西省基层医疗卫生机构基本药物制度实施效果评估研究[J].中国药事, 2014, 28(11): 1173-1177. WU Lina, WEI Dehong, CHEN Chen, et al. Study on the implementation of essential medicine policy in primary care institutions in Shaanxi Province[J]. Chinese Pharmaceutical Affairs, 2014, 28(11): 1173-1177.
[15] 姜明欢,王乐,王文娟,等.陕西省公立医院基本药物制度实施状况评估[J].中华医院管理杂志, 2013, 29(5): 347-352. JIANG Minghuan, WANG Le, WNAG Wenjuan, et al. Assessment of the implementations of the essential medicine policy in public hospitals in Shaanxi Province[J]. Chin J Hosp Admin, 2013, 29(5): 347-352.
[16] 袁泉,邵蓉.基本药物可获得性障碍研究[J].上海医药, 2010, 31(3): 116-118.
[17] 吴建华,刘萍,吴东方,等.基于国外经验的基本药物可获得性和可及性探讨[J].中国药房, 2011, 22(20): 1833-1835. WU Jianhua, LIU Ping, WU Dongfang, et al. Investigation of the availability and accessibility of essential drugs based on experience abroad[J]. China Pharmacy, 2011, 22(20): 1833-1835.
[18] Sun Q. A survey of medicine prices, availability, affordability and price components in Shandong Province, China contents[EB/OL].(2005-10-01)[2016-12-07] http://www.haiweb.org/medicineprices/surveys/200411CN/survey_report.pdf.
[19] Lu YE. A survey of medicine prices, availability and affordability in Shanghai, China using the WHO/HAI methodology[EB/OL].(2006-12-01)[2016-12-07]. http://haiweb.org/wp-content/uploads/2015/07/China-Shanghai-Report-Pricing-Surveys.pdf.
[20] Yang H, Dib HH, Zhu M. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China[J]. Health Policy Plan, 2010, 25(3): 219-229.
[21] 徐伟,殷丹妮.江苏省基本药物可负担性实证研究[J].上海医药, 2012, 33(3):43-47. XU Wei, YIN Danni. Evidence-base study on the affordability of essential medicines in Jiangsu Province[J]. Shanghai Medical & Pharmaceutical Journal, 2012, 33(3): 43-47.
[22] 李萍,吕景睿,阳昊,等.湖北省农村居民基本药物可负担性研究[J].医学与社会, 2010, 23(2): 18-20. LI Ping, LÜ Jingrui, YANG Hao, et al. Study on the affordablity of essential medicines in rural areas of Hubei Province[J]. Medicine and Society, 2010, 23(2): 18-20.
[23] 徐伟,殷丹妮.我国基本药物可负担性实证研究[J].中国药房, 2012(40): 3745-3747. XU Wei, YIN Danni. Empirical study on the affordability of essential drugs in China[J]. China Pharmacy, 2012(40): 3745-3747.
[24] Thomas R, Vitry A. Consumers perception of generic medicines in community pharmacies in Malaysia[J]. South Med Rev, 2009, 2(2): 20-23.
[25] 蒋华,刘涛,陈文芳.社区老年人用药安全现状及对策研究[J].中国实用护理杂志, 2011, 27(28): 64-65.
[26] Chuc NT, Larsson M, Do NT, et al Improving private pharmacy practice: a multiintervention experiment in Hanoi, Vietnam[J]. J Clin Epidemiol, 2002, 55(11): 1148-1155.
[1] DONG Xue, ZHAO Xia, CHENG Zijie, HAN Yi. Pharmacoeconomic evaluation of levosimendan and milrinone in the treatment of 711 patients with severe heart failure complicated with renal injury [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 91-98.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] WANG Huan-liang,SUN Bao-zhu,DU Hong-mei,ZHOU Chang-qing,ZHANG Li. Controlling the depth of propofol anesthesia using the bispectral indexand the systolic blood pressure[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(5): 471 -474 .
[2] HUANGQing,TIAN Hui,LI Lin,LIANG Fei,LIU Xi-xian. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(6): 556 -559 .
[3] ZHU Mei-jia,HAN Ju,WANG Xin-yi,LU Wei,WANG Ai-hua,GUAN Xin-hua,CAO Xia,CAO Bing-zhen. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(8): 834 -839 .
[4] SONG Yong-hong,MA Chun-hong,LV Hong-juan,ZHU Chuan-fu,NIE Xiang-min,WANG Mei,LIU Yan,ZHANG Ping. HLA allele polymorphism in northern Hans of China[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(6): 546 -553 .
[5] ZENG Ji-ping,WANG Li-na,WANG Li-xiang,REN Xiao-hui,ZHANG Meng-ye,XIA Wen,CUI Xing. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(5): 467 -470 .
[6] SHU Ya,QI Feng. Jaw thrust device (JTD) on obesity patients for maintaining the airway patency during general anesthesia induction[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(10): 1072 -1074 .
[7] SONG Hai-yan, WU Yu-ling, ZHANG Yan-ping. Protective effect of oyster extract on apoptotic cells in neural tube defect induced by hyperthermia[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(2): 113 -116 .
[8] HOU Xiao-yang,BU Pei-li,ZHANG Yun,FENG Jin-bo,LIU Chun-xi,LI Chuan-bao,HAO Ming-xiu. Peroxisome proliferatorsactivated receptor α play a critical role in the inhibition of myocardial fibrosis induced by AngⅡ in vitro[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(7): 665 -668 .
[9] WANG Zhi-ang,DING Xua,SUN Peng/sup>,WANG Cheng-wei,HAO Xiao-guang,PAN Shun. Role of pre-operative cerebral angiography in cerebral artery stenosis stent angioplasty[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(2): 146 -148 .
[10] ZHENG Jin-Xu, GU Yan-Lan, WAN Bing. Effect of chymase inhibitor on bleomycininduced pulmonary fibrosis and its mechanism in rats[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(12): 1132 -1135 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd